This role is critical for supporting the US commercialization of COBENFY, the first treatment targeting muscarinic receptor circuits for schizophrenia.
Base: $139,230 - $168,714; Bonus/Equity: Additional incentive cash and stock opportunities available; Benefits: Medical, dental, vision, 401(k), paid time off, and wellbeing support programs
Must-have
Nice-to-have
Not specified